Abstract 316P
Background
In the United States (US), eribulin mesylate has been approved for metastatic breast cancer (mBC) in the third-line or later after prior treatment with an anthracycline and a taxane in the adjuvant or metastatic setting since 2010. With evolving treatment landscape in mBC over the last ten years, the main objective of the current study was to assess real-world clinical effectiveness in a cohort of mBC patients treated with eribulin in the US in accordance with the US prescribing information (USPI).
Methods
A retrospective chart review study was conducted across community oncology practices in the US; the sample included patients with mBC who had initiated treatment with eribulin as per USPI between 2011 and 2017. Data were extracted by prescribing physicians from individual patients’ electronic health records and captured via an electronic case report form. All patient data were de-identified prior to analyses. Clinical outcomes assessed included provider-reported objective response rate (ORR), progression-free survival (PFS) and overall survival (OS) in all patients and those with triple negative breast cancer (TNBC), respectively.
Results
Current analyses were based on data from 278 patients, of which 150 patients (54%) were of TNBC subtype. Average age of eribulin-treated patients was 60 years and 60% of the patients had ECOG status 0 or 1. In the TNBC subgroup, average age was 57 years; 65% had ECOG status 0 or 1. A greater proportion of patients with TNBC were treated with eribulin in 3rd line (93%) compared with the overall patient cohort (80%), with the remainder treated in 4th line or greater. ORR was approximately 50% in all patients and the TNBC subgroup. Median PFS was 6 and 6.2 months for the total sample and the TNBC subgroup, respectively. Landmark OS at 6, 12 and 24 months in all patients was 78%, 45% and 25%, respectively. Landmark OS at 6, 12 and 24 months in the TNBC subgroup was 78%, 45% and 21%, respectively.
Conclusions
Results from the current study reinforce clinical effectiveness of eribulin in mBC patients and those with TNBC when used in accordance with the US label in real-world clinical practice.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Cardinal Health.
Funding
Eisai Inc.
Disclosure
S.S. Mougalian: Advisory/Consultancy: Eisai, Inc.; Advisory/Consultancy: Celgene; Research grant/Funding (institution): Pfizer; Research grant/Funding (institution): Genentech. J.K. Kish: Full/Part-time employment: Cardinal Health. J. Zhang: Full/Part-time employment: Eisai, Inc.. T. Miller: Full/Part-time employment: Cardinal Health. D. Liassou: Full/Part-time employment: Cardinal Health. J. Laney: Full/Part-time employment: Cardinal Health. S. Iyer: Full/Part-time employment: Eisai, Inc.; Shareholder/Stockholder/Stock options: Pfizer.